Opens in a new tab or window For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban.

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Taho Pharmaceuticals’s apixaban-based oral dissolving strips were discovered to be a bioequivalent of Pfizer and Bristol-Myers Squibb’s (BMS) Eliquis in a Phase II trial. The randomised open ...

A new study from the University of Bath has found that for older adults with atrial fibrillation (AF), stopping blood ...

The results showed that patients taking diltiazem had a 20% higher risk of being hospitalized or dying due to serious ...

For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants (OACs) may carry a higher bleeding risk ...

An inquest into the death of veteran actor Tony Mathews has concluded that the 81-year-old died because his heart could not ...

As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in ...

Welcome to Medicare Part D, where your prescription drugs come with co-pays and co-insurance. If you thought co-pays and ...